796967-84-5

Basic information

• Product Name: 4-Iodo-1-methyl-1H-indazol-3-ylamine
• Synonyms: 3-Amino-4-iodo-1-methyl-1H-indazole;4-Iodo-1-methyl-1H-indazol-3-ylamine
• CAS NO: 796967-84-5
• Molecular Formula: C₈H₈IN₃
• Molecular Weight: 273.07369
• Mol File: 796967-84-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Iodo-1-methyl-1H-indazol-3-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Iodo-1-methyl-1H-indazol-3-ylamine(796967-84-5)
• EPA Substance Registry System: 4-Iodo-1-methyl-1H-indazol-3-ylamine(796967-84-5)

Safety Data

• Hazardous Substances Data: 796967-84-5(Hazardous Substances Data)

Upstream product

• 79544-29-9 2-fluoro-6-iodobenzonitrile 
• 60-34-4 methylhydrazine 

Downstream Products

• 796967-85-6 4-(4-aminophenyl)-1-methyl-1H-indazol-3-amine 
• 1391069-41-2 C₁₀H₁₁N₃O₂ 

Relevant articles and documents

NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF

The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comp

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5- methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor

In our continued efforts to search for potent and novel receptor tyrosine kinase (RTK) inhibitors as potential anticancer agents, we discovered, through a structure-based design, that 3-aminoindazole could serve as an efficient hinge-binding template for kinase inhibitors. By incorporating an N,N′-diaryl urea moiety at the C4-position of 3-aminodazole, a series of RTK inhibitors were generated, which potently inhibited the tyrosine kinase activity of the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor families. A number of compounds with potent oral activity were identified by utilizing an estradiol-induced mouse uterine edema model and an HT1080 human fibrosarcoma xenograft tumor model. In particular, compound 17p (ABT-869) was found to possess favorable pharmacokinetic profiles across different species and display significant tumor growth inhibition in multiple preclinical animal models.

Indazole and benzisoxazole kinase inhibitors

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.